

Rui Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9662446/publications.pdf>

Version: 2024-02-01

11
papers

424
citations

1478505

6
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

710
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative comparison of doseâ€“effect and timeâ€“course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and metaâ€“analysis. <i>Respirology</i> , 2022, , .	2.3	2
2	Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of nonâ€“small cell lung cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 986-994.	1.5	1
3	Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer. <i>Pharmacological Research</i> , 2021, 165, 105442.	7.1	28
4	A New Measure of Pulse Rate Variability and Detection of Atrial Fibrillation Based on Improved Time Synchronous Averaging. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-9.	1.3	4
5	Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 771836.	3.5	0
6	Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1231-1240.	4.1	3
7	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	5.4	90
8	Exosomes in hepatocellular carcinoma: a new horizon. <i>Cell Communication and Signaling</i> , 2019, 17, 1.	6.5	115
9	Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3962-3970.	2.5	25
10	The Role of MicroRNAs in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3557-3569.	2.5	128
11	The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. <i>Discovery Medicine</i> , 2018, 26, 155-166.	0.5	28